Form 4: Royalty Pharma Executive Receives Stock Grant
Insider Transaction (Form 4)
Marshall Urist, EVP, Research & Investments of Royalty Pharma plc, reported multiple transactions in common stock on November 4, 2026.
Summary
- Grant/award: acquired 5,341 Class A Ordinary Shares on November 4, 2026; holds 5,341 after (Direct).
- Conversion of derivative: acquired 150,000 Class A Ordinary Shares on November 6, 2026; holds 150,000 after (Indirect).
- Conversion of derivative: disposed of 15,000 LP interests in RPI US Partners 2019, LP on November 6, 2026; holds 229,412 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Marshall Urist — Officer (EVP, Research & Investments)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-04 | Grant/award | Class A Ordinary Shares | 5,341 | — | — | 5,341 |
| 2026-11-06 | Conversion of derivative | Class A Ordinary Shares | 150,000 | — | — | 150,000 |
| 2026-11-06 | Conversion of derivative | LP interests in RPI US Partners 2019, LP | 15,000 | — | — | 229,412 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-04 | Grant/award (5,341 shares) |
| 2026-11-06 | Conversion of derivative (150,000 shares) |
| 2026-11-06 | Conversion of derivative (15,000 shares) |
Keywords
insider transaction, Form 4, RPRX, Royalty Pharma plc, neutral, Marshall Urist
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.